We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Blocking Fails to Stop Tumor Growth

By Biotechdaily staff writers
Posted on 19 Jan 2005
Cancer researchers have found that blocking genes to prevent tumor growth is only temporarily successful, as cells that survive the treatment grow back in a manner that is often no longer regulated by the gene.

Investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA; www.med.upenn.edu) worked with a mouse model to study the effect of blocking c-MYC regulation on mammary cancer. More...
C-Myc, a proto-oncogene located at 8q24, is a member of the Myc gene family that also includes the closely related N-Myc, L-Myc, P-Myc, R-Myc, S-Myc, and B-Myc genes. C-Myc spans 6-7 kb of genomic DNA, and codes for 439 amino acids. The C-Myc gene encodes a 66 kDa nuclear DNA-binding protein that regulates gene transcription and is responsible for growth control and cell cycle progression. The location of the C-Myc gene has been identified as one of the three most commonly amplified genomic regions in breast cancer, and C-Myc overexpression has been described in 70-100% of breast cancer tissues.

Previous research had suggested that preventing C-Myc expression would stop the growth of mammary cancers. However, results published in the December 2004 issue of Cancer Cell revealed that 50% of c-Myc-induced mammary cancers were able to grow in a mouse model lacking c-Myc expression. In addition, residual cancer cells remained from virtually all tumors that did regress, and these residual cells rapidly recovered their malignant properties following c-MYC reactivation or spontaneously recurred in a MYC-independent manner.

Senior author Dr. Lewis A. Chodosh, associate professor of cancer biology and medicine at the University of Pennsylvania School of Medicine, explained, "When physicians apply a selective pressure to a tumor by blocking an oncogenic pathway, cells escape. They find a back door and progress to a more aggressive state that becomes independent of that pathway.”




Related Links:
University of Pennsylvania School of Medicine

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.